These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 26729008)

  • 1. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
    Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
    J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.
    Hodgkin D; Horgan CM; Quinn AE; Merrick EL; Stewart MT; Leslie LK
    Clin Ther; 2014 Dec; 36(12):2034-2046. PubMed ID: 25450473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of access to branded psychotropic medications in private health plans.
    Hodgkin D; Horgan CM; Garnick DW; Len Merrick E; Volpe-Vartanian J
    Clin Ther; 2007 Feb; 29(2):371-80. PubMed ID: 17472830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
    Cecil WT; Barnes J; Shea T; Coulter SL
    J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Availability of addiction medications in private health plans.
    Horgan CM; Reif S; Hodgkin D; Garnick DW; Merrick EL
    J Subst Abuse Treat; 2008 Mar; 34(2):147-56. PubMed ID: 17499959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of antidepressant prescribing concentration to treatment duration and cost.
    Hodgkin D; Merrick EL; Hiatt D
    J Ment Health Policy Econ; 2012 Mar; 15(1):3-11. PubMed ID: 22611088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
    Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
    JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs.
    Briesacher B; Kamal-Bahl S; Hochberg M; Orwig D; Kahler KH
    Arch Intern Med; 2004 Aug 9-23; 164(15):1679-84. PubMed ID: 15302639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans.
    Ben-Joseph R; Chen CC; De AP; Wade RL; Shah D
    J Med Econ; 2014 Oct; 17(10):708-18. PubMed ID: 24888403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insurance coverage and the treatment of mental illness: effect on medication and provider use.
    Mulvale G; Hurley J
    J Ment Health Policy Econ; 2008 Dec; 11(4):177-99. PubMed ID: 19096092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan.
    Nau DP; Chi C; Mallya U; Kirking DM
    J Manag Care Pharm; 2007 Mar; 13(2):135-41. PubMed ID: 17330974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in mental health insurance benefits and out-of-pocket spending.
    McKusick DR; Mark TL; King EC; Coffey RM; Genuardi J
    J Ment Health Policy Econ; 2002 Jun; 5(2):71-8. PubMed ID: 12529560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Determines How Much Your Patient Pays for Their Medication in the United States?
    Novack GD
    Am J Ophthalmol; 2016 Jul; 167():48-51. PubMed ID: 27131775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.